Previous close | 1,705.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 8,263,272 |
Market cap | 70.489B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 15.86 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.60 (3.52%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
GSK ( LON:GSK ) First Quarter 2024 Results Key Financial Results Revenue: UK£7.36b (up 5.9% from 1Q 2023). Net income...
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.